The role of microemulsion technology in psoriasis treatment: an evaluation in light of clinical and preclinical findings

Nurseli Saylam; Elif Gün; Özlem Çoban; Gülgun Yener

doi:10.12991/jrespharm.1763606

The role of microemulsion technology in psoriasis treatment: an evaluation in light of clinical and preclinical findings

Abstract

Psoriasis is a chronic, inflammatory, and immune mediated dermatological diseases that adversely affects the quality of life of millions of individuals worldwide. Due to its heterogeneous natüre, which varies from patient to patient, and its systemic manifestations, current treatment approaches are often insufficient and make disease management challenging. This complex pathophysiology has increasingly highlighted the need for more targeted and effective drug delivery systems beyond conventional therapeutic strategies. In recent years, nanotechnology-based drug delivery strategies have attracted attention in psoriasis treatment due to their potential to offer more effective pharmacodynamic profiles and reduce undesirable systemic effects. Among these, microemulsion systems are considered innovative delivery platforms thanks to their high stability, ability to penetrate biological barriers, and controlled release properties. Recent preclinical studies have demonstrated that these formulations can significantly enhance anti-inflammatory, immunomodulatory, and antiproliferative effects. This review aims to evaluate therapeutic potential, formulation techniques, pharmaceutical performance, and translational possibilities of microemulsion-based delivery systems considering preclinical studies published between 2019 and 2024.

Keywords

Supporting Institution

None

Ethical Statement

An ethical approval is not required for this review article, as it does not involve human or animal subjects.

Thanks

None

References

[1] Korman NJ. Management of psoriasis as a systemic disease: what is the evidence? British Journal of Dermatology 2020;182:840–8. https://doi.org/10.1111/BJD.18245.
[2] Mounsey SJ, Kulakov E. Psoriasis. Br J Hosp Med (Lond) 2018;79:C114–7. https://doi.org/10.12968/HMED.2018.79.8.C114/ASSET/HMED.2018.79.8.C114.FP.PNG_V03.
[3] Global Psoriasis Atlas. Global Psoriasis Atlas n.d. https://www.globalpsoriasisatlas.org (accessed August 11, 2025)
[4] Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ 2020;369. https://doi.org/10.1136/BMJ.M1590.
[5] Kamiya K, Kishimoto M, Sugai J, Komine M, Ohtsuki M. Risk Factors for the Development of Psoriasis. Int J Mol Sci 2019;20:4347. https://doi.org/10.3390/IJMS20184347.
[6] Mahil SK, Capon F, Barker JN. Genetics of Psoriasis. Dermatol Clin 2015;33:1–11. https://doi.org/10.1016/J.DET.2014.09.001,.
[7] Furue M, Kadono T. Psoriasis: Behind the scenes. Journal of Dermatology 2016;43:4–8. https://doi.org/10.1111/1346-8138.13186,.
[8] Rendon A, Schäkel K. Psoriasis Pathogenesis and Treatment. Int J Mol Sci 2019;20:1475. https://doi.org/10.3390/IJMS20061475.

[9] Yamazaki F. Psoriasis: Comorbidities. Journal of Dermatology 2021;48:732–40. https://doi.org/10.1111/1346-8138.15840,.
[10] Prodanovich S, Kirsner RS, Kravetz JD, Ma F, Martinez L, Federman DG. Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol 2009;145:700–3. https://doi.org/10.1001/ARCHDERMATOL.2009.94,.
[11] Armstrong AW, Mehta MD, Schupp CW, Gondo GC, Bell SJ, Griffiths CEM. Psoriasis Prevalence in Adults in the United States. JAMA Dermatol 2021;157:940–6. https://doi.org/10.1001/JAMADERMATOL.2021.2007.
[12] Kundakci N, Türsen Ü, Babiker MOA, Gürgey E. The evaluation of the sociodemographic and clinical features of Turkish psoriasis patients. Int J Dermatol 2002;41:220–4. https://doi.org/10.1046/J.1365-4362.2002.01462.X,.
[13] Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007;370:263–71. https://doi.org/10.1016/S0140-6736(07)61128-3.
[14] Barker JNWN. Pathogenesis of Psoriasis. J Dermatol 1998;25:778–81. https://doi.org/10.1111/J.1346-8138.1998.TB02504.X.
[15] Ortonne JP. Aetiology and pathogenesis of psoriasis. British Journal of Dermatology, Supplement 1996;135:1–5. https://doi.org/10.1111/J.1365-2133.1996.TB15660.X,.
[16] Takahashi T, Yamasaki K. Psoriasis and Antimicrobial Peptides. Int J Mol Sci 2020;21:6791. https://doi.org/10.3390/IJMS21186791.
[17] Boehncke WH. Etiology and Pathogenesis of Psoriasis. Rheumatic Disease Clinics of North America 2015;41:665–75. https://doi.org/10.1016/j.rdc.2015.07.013.
[18] Blauvelt A, Chiricozzi A. The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis. Clin Rev Allergy Immunol 2018;55:379–90. https://doi.org/10.1007/S12016-018-8702-3,.
[19] Singh R, Koppu S, Perche PO, Feldman SR. The cytokine mediated molecular pathophysiology of psoriasis and its clinical implications. Int J Mol Sci 2021;22. https://doi.org/10.3390/IJMS222312793,.
[20] Brembilla NC, Senra L, Boehncke WH. The IL-17 family of cytokines in psoriasis: IL-17A and beyond. Front Immunol 2018;9. https://doi.org/10.3389/FIMMU.2018.01682,.
[21] Grän F, Kerstan A, Serfling E, Goebeler M, Muhammad K. Current developments in the immunology of psoriasis. Yale Journal of Biology and Medicine 2020;93:97–110.
[22] Greaves MW, Weinstein GD. Treatment of psoriasis. N Engl J Med 1995;332:581–9. https://doi.org/10.1056/NEJM199503023320907.
[23] Lee HJ, Kim M. Challenges and Future Trends in the Treatment of Psoriasis. Int J Mol Sci 2023;24. https://doi.org/10.3390/IJMS241713313,.
[24] Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Canadian Family Physician 2017;63:278. https://doi.org/10.59783/aire.2023.5.
[25] Cather JC, Crowley JJ. Use of Biologic Agents in Combination with Other Therapies for the Treatment of Psoriasis. Am J Clin Dermatol 2014;15:467. https://doi.org/10.1007/S40257-014-0097-1.
[26] Van de Kerkhof PCM, Kragballe K. Recommendations for the topical treatment of psoriasis. Journal of the European Academy of Dermatology and Venereology 2005;19:495–9. https://doi.org/10.1111/J.1468-3083.2005.01198.X,.
[27] Hafeez F, Chiang A, Hui X, Zhu H, Kamili F, Maibach HI. Stratum corneum reservoir as a predictive method for in vitro percutaneous absorption. Journal of Applied Toxicology 2016;36:1003–10. https://doi.org/10.1002/JAT.3262,.
[28] Jadhav K, Shaikh I, Ambade K, Kadam V. Applications of Microemulsion Based Drug Delivery System. Curr Drug Deliv 2006;3:267–73. https://doi.org/10.2174/156720106777731118,.
[29] Das S, Lee SH, Chia VD, Chow PS, Macbeath C, Liu Y, Shlieout G. Development of microemulsion based topical ivermectin formulations: Pre-formulation and formulation studies. Colloids Surf B Biointerfaces 2020;189. https://doi.org/10.1016/j.colsurfb.2020.110823.
[30] Assaf S, Maaroof K, Altaani B, Ghareeb M, Abu Alhayyal A. Jojoba oil-based microemulsion for transdermal drug delivery. Res Pharm Sci 2021;16:326–40. https://doi.org/10.4103/1735-5362.319572,.
[31] Hoar TP, Schulman JH. Transparent water-in-oil dispersions: The oleopathic hydro-micelle [1]. Nature 1943;152:102–3. https://doi.org/10.1038/152102A0;KWRD=SCIENCE.
[32] Danielsson I, Lindman B. The definition of microemulsion. Colloids and Surfaces 1981;3:391–2. https://doi.org/10.1016/0166-6622(81)80064-9.
[33] Çilek’ A, Türkyilmaz’ A, Çelebi N. Mikroemü lsiyonlar: Genel Özellikler i ve Farmasöti k Amaçla Kullanımla rı. vol. 27. 2002.
[34] Lawrence MJ, Rees GD. Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev 2000;45:89–121. https://doi.org/10.1016/S0169-409X(00)00103-4.
[35] Suhail N, Alzahrani AK, Basha WJ, Kizilbash N, Zaidi A, Ambreen J, Khachfe HM. Microemulsions: Unique Properties, Pharmacological Applications, and Targeted Drug Delivery. Frontiers in Nanotechnology 2021;3:754889. https://doi.org/10.3389/FNANO.2021.754889/BIBTEX.
[36] Muzaffar F, Singh U, Chauhan L. ON MICROEMULSION AS FUTURISTIC DRUG DELIVERY 2013.
[37] Tartaro G, Mateos H, Schirone D, Angelico R, Palazzo G. Microemulsion Microstructure(s): A Tutorial Review. Nanomaterials 2020, Vol 10, Page 1657 2020;10:1657. https://doi.org/10.3390/NANO10091657.
[38] El-Zaafarany GM, Nasr M. Insightful exploring of advanced nanocarriers for the topical/transdermal treatment of skin diseases. Pharm Dev Technol 2021;26:1136–57. https://doi.org/10.1080/10837450.2021.2004606.
[39] Pandey S, Tripathi P, Gupta A, Yadav JS. A comprehensive review on possibilities of treating psoriasis using dermal cyclosporine. Drug Delivery and Translational Research 2021 12:7 2021;12:1541–55. https://doi.org/10.1007/S13346-021-01059-5.
[40] Chen H, Chang X, Du D, Li J, Xu H, Yang X. Microemulsion-based hydrogel formulation of ibuprofen for topical delivery. Int J Pharm 2006;315:52–8. https://doi.org/10.1016/J.IJPHARM.2006.02.015.
[41] Rhee YS, Choi JG, Park ES, Chi SC. Transdermal delivery of ketoprofen using microemulsions. Int J Pharm 2001;228:161–70. https://doi.org/10.1016/S0378-5173(01)00827-4.
[42] Peltola S, Saarinen-Savolainen P, Kiesvaara J, Suhonen TM, Urtti A. Microemulsions for topical delivery of estradiol. Int J Pharm 2003;254:99–107. https://doi.org/10.1016/S0378-5173(02)00632-4.
[43] Badawi AA, Nour SA, Sakran WS, Mohamed S, El-Mancy S. Preparation and Evaluation of Microemulsion Systems Containing Salicylic Acid n.d. https://doi.org/10.1208/s12249-009-9301-7.
[44] Shakeel F, Baboota S, Ahuja A, Ali J, Shafiq S. Skin permeation mechanism and bioavailability enhancement of celecoxib from transdermally applied nanoemulsion. J Nanobiotechnology 2008;6:1–11. https://doi.org/10.1186/1477-3155-6-8/TABLES/2.
[45] Abd E, Namjoshi S, Mohammed YH, Roberts MS, Grice JE. Synergistic Skin Penetration Enhancer and Nanoemulsion Formulations Promote the Human Epidermal Permeation of Caffeine and Naproxen. J Pharm Sci 2016;105:212–20. https://doi.org/10.1002/JPS.24699.
[46] Guo J-W, Cheng Y-P, Liu C-Y, Thong H-Y, Huang C-J, Lo Y, Wu C-Y, Jee S-H. pharmaceutics Salvianolic Acid B in Microemulsion Formulation Provided Sufficient Hydration for Dry Skin and Ameliorated the Severity of Imiquimod-induced Psoriasis-like Dermatitis in Mice 2020. https://doi.org/10.3390/pharmaceutics12050457.
[47] Pandey SS, Maulvi FA, Patel PS, Shukla MR, Shah KM, Gupta AR, Joshi S V., Shah DO. Cyclosporine laden tailored microemulsion-gel depot for effective treatment of psoriasis: In vitro and in vivo studies. Colloids Surf B Biointerfaces 2020;186:110681. https://doi.org/10.1016/J.COLSURFB.2019.110681.
[48] Chen LC, Cheng YP, Liu CY. Lithosepermic Acid Restored the Skin Barrier Functions in the Imiquimod-Induced Psoriasis-like Animal Model. Int J Mol Sci 2022;23. https://doi.org/10.3390/IJMS23116172,.
[49] He E, Li H, Li X, Wu X, Lei K, Diao Y. Transdermal Delivery of Indirubin-Loaded Microemulsion Gel: Preparation, Characterization and Anti-Psoriatic Activity. Int J Mol Sci 2022;23:3798. https://doi.org/10.3390/IJMS23073798.
[50] Guo JW, Cheng YP, Lim CJ, Liu CY, Jee SH. A Promising Approach to Treat Psoriasis: Inhibiting Cytochrome P450 3A4 Metabolism to Enhance Desoximetasone Therapy. Pharmaceutics 2023;15:2016. https://doi.org/10.3390/PHARMACEUTICS15082016/S1.
[51] Kakade P, Patravale V, Patil A, Disouza J. Formulation development of nanostructured lipid carrier-based nanogels encapsulating tacrolimus for sustained therapy of psoriasis. Int J Pharm 2024;660. https://doi.org/10.1016/J.IJPHARM.2024.124172,.
[52] ClinicalTrials.gov. A study to evaluate the safety and efficacy of cyclosporine microemulsion in patients with chronic plaque psoriasis (NCT00438360). Available from: https://clinicaltrials.gov/study/NCT00438360. Accessed: 02 Aug 2025.
[53] ClinicalTrials.gov. A study to evaluate the safety and efficacy of topical ruxolitinib cream in patients with chronic plaque psoriasis (NCT04971239). Available from: https://clinicaltrials.gov/study/NCT04971239. Accessed: 02 Aug 2025.
[54] El-Gogary RI, Ragai MH, Moftah N, Nasr M. Oleuropein as a novel topical antipsoriatic nutraceutical: formulation in microemulsion nanocarrier and exploratory clinical appraisal. Expert Opin Drug Deliv 2021;18:1523–32. https://doi.org/10.1080/17425247.2021.1932813,.
[55] Vejjabhinanta V, Muangsiri W, Werawatganone P. Fluocinolone Acetonide Microemulsion in Combination with a Fractional Laser for the Treatment of Scalp Psoriasis. AAPS PharmSciTech 2022;23. https://doi.org/10.1208/S12249-022-02249-1,.
[56] Zachariae H, Steen Olsen T. Efficacy of cyclosporin A (CyA) in psoriasis: an overview of dose/response, indications, contraindications and side-effects - PubMed. Clin Nephrol 1995;43:154–8.
[57] Meinardi MMHM, De Rie MA, Bos JD. Oral cyclosporin A in the treatment of psoriasis: An overview of studies performed in The Netherlands. British Journal of Dermatology 1990;122:27–31. https://doi.org/10.1111/J.1365-2133.1990.TB02879.X,.
[58] Heule F, Laijendecker R, van Joost T. Topical cyclosporin a treatment in psoriasis and other dermatological diseases: Theoretical and practical aspects. Journal of Dermatological Treatment 1992;2:149–53. https://doi.org/10.3109/09546639209092744,.
[59] Sadeghi S, Kalantari Y, Seirafianpour F, Goodarzi A. A systematic review of the efficacy and safety of topical cyclosporine in dermatology. Dermatol Ther 2022;35. https://doi.org/10.1111/DTH.15490,.
[60] Baveja S, Neema S, Pathania V, Kothari R. Tacrolimus as a therapeutic alternative in psoriasis: A retrospective observational study. Indian J Dermatol Venereol Leprol 2022;88:247–9. https://doi.org/10.25259/IJDVL_1229_20.
[61] Rallis E, Korfitis C, Gregoriou S, Rigopoulos D. Assigning new roles to topical tacrolimus. Expert Opin Investig Drugs 2007;16:1267–76. https://doi.org/10.1517/13543784.16.8.1267.
[62] Swanson HI. Cytochrome P450 expression in human keratinocytes: an aryl hydrocarbon receptor perspective. Chem Biol Interact 2004;149:69–79. https://doi.org/10.1016/J.CBI.2004.08.006.
[63] Mountfield RJ, Senepin S, Schleimer M, Walter I, Bittner B. Potential inhibitory effects of formulation ingredients on intestinal cytochrome P450. Int J Pharm 2000;211:89–92. https://doi.org/10.1016/S0378-5173(00)00586-X.
[64] Bravo González RCB, Huwyler J, Boess F, Walter I, Bittner B. In vitro investigation on the impact of the surface-active excipients Cremophor EL, Tween 80 and Solutol HS 15 on the metabolism of midazolam. Biopharm Drug Dispos 2004;25:37–49. https://doi.org/10.1002/BDD.383,.

Details

Primary Language

English

Subjects

Pharmaceutical Delivery Technologies, Clinical Pharmacology and Therapeutics, Basic Pharmacology

Journal Section

Review

Authors

Nurseli Saylam ^*
0009-0000-5080-2747
Türkiye

Elif Gün
0000-0003-4854-3701
Türkiye

Özlem Çoban
0000-0003-1154-7602
Türkiye

Gülgun Yener
0000-0002-7234-0034
Türkiye

Publication Date

May 11, 2026

Submission Date

August 14, 2025

Acceptance Date

October 27, 2025

Published in Issue

Year 2026 Volume: 30 Number: 3

DOI

https://doi.org/10.12991/jrespharm.1763606

IZ

https://izlik.org/JA85RJ33JR

Cite

RIS / Bibtex

APA

Saylam, N., Gün, E., Çoban, Ö., & Yener, G. (2026). The role of microemulsion technology in psoriasis treatment: an evaluation in light of clinical and preclinical findings. Journal of Research in Pharmacy, 30(3), 882-894. https://doi.org/10.12991/jrespharm.1763606

AMA

1.Saylam N, Gün E, Çoban Ö, Yener G. The role of microemulsion technology in psoriasis treatment: an evaluation in light of clinical and preclinical findings. J. Res. Pharm. 2026;30(3):882-894. doi:10.12991/jrespharm.1763606

Chicago

Saylam, Nurseli, Elif Gün, Özlem Çoban, and Gülgun Yener. 2026. “The Role of Microemulsion Technology in Psoriasis Treatment: An Evaluation in Light of Clinical and Preclinical Findings”. Journal of Research in Pharmacy 30 (3): 882-94. https://doi.org/10.12991/jrespharm.1763606.

EndNote

Saylam N, Gün E, Çoban Ö, Yener G (May 1, 2026) The role of microemulsion technology in psoriasis treatment: an evaluation in light of clinical and preclinical findings. Journal of Research in Pharmacy 30 3 882–894.

IEEE

[1]N. Saylam, E. Gün, Ö. Çoban, and G. Yener, “The role of microemulsion technology in psoriasis treatment: an evaluation in light of clinical and preclinical findings”, J. Res. Pharm., vol. 30, no. 3, pp. 882–894, May 2026, doi: 10.12991/jrespharm.1763606.

ISNAD

Saylam, Nurseli - Gün, Elif - Çoban, Özlem - Yener, Gülgun. “The Role of Microemulsion Technology in Psoriasis Treatment: An Evaluation in Light of Clinical and Preclinical Findings”. Journal of Research in Pharmacy 30/3 (May 1, 2026): 882-894. https://doi.org/10.12991/jrespharm.1763606.

JAMA

1.Saylam N, Gün E, Çoban Ö, Yener G. The role of microemulsion technology in psoriasis treatment: an evaluation in light of clinical and preclinical findings. J. Res. Pharm. 2026;30:882–894.

MLA

Saylam, Nurseli, et al. “The Role of Microemulsion Technology in Psoriasis Treatment: An Evaluation in Light of Clinical and Preclinical Findings”. Journal of Research in Pharmacy, vol. 30, no. 3, May 2026, pp. 882-94, doi:10.12991/jrespharm.1763606.

Vancouver

1.Nurseli Saylam, Elif Gün, Özlem Çoban, Gülgun Yener. The role of microemulsion technology in psoriasis treatment: an evaluation in light of clinical and preclinical findings. J. Res. Pharm. 2026 May 1;30(3):882-94. doi:10.12991/jrespharm.1763606